1. Introduction {#sec1}
===============

Disproportionation reactions generally furnish a 1:1 mixture of products and are often plagued by unfavorable equilibria, hence they are commonly considered as inefficient and are rarely used in organic synthesis.[@bib1] In biology, the disproportionation of sulfur yielding hydrogen sulfide and sulfate and of hydrogen peroxide furnishing O~2~ and H~2~O represent the most dominant disproportionation processes in Nature.[@bib2] The disproportionation of cyclohex-2-enone, forming equimolar amounts of cyclohexanone and phenol has been described for several flavoproteins from the old yellow enzyme (OYE) family, such as OYE isoenzymes 1--3 and estrogen-binding protein.[@bib3; @bib3a; @bib3b; @bib3c] In the context of these studies, this phenomenon has been considered either as a minor side reaction demonstrating the catalytic promiscuity[@bib4] of OYEs or as 'aromatase' activity of enoate reductases catalyzing the formation of the phenolic A-ring in steroids, such as 17β-estradiol, from the corresponding enone-precursor 19-nortestosterone.[@bib3; @bib3a; @bib3b; @bib3c] Overall, this reaction constitutes a flavin-dependent hydrogen transfer, during which an equivalent of \[2H\] is formally transferred from a cyclohex-2-enone (being oxidized) onto another one (being reduced). The oxidized product constitutes a conjugated dienone, which spontaneously tautomerises to form phenol, thereby providing a large driving force of ca. −30 kcal/M for the disproportionation reaction. During this hydrogen-transfer reaction, the flavin-cofactor is recycled internally and no external nicotinamide cofactor is required for the reductive half-reaction.[@bib5; @bib5a; @bib5b] In nicotinamide-dependent systems, CC-bonds are reduced at the expense of an external hydride donor,[@bib6] such as formate, glucose, glucose-6-phosphate or phosphite, which requires a second dehydrogenase enzyme, such as FDH, GDH, G6PDH[@bib7] or phosphite-DH,[@bib8] respectively. This technology is generally denoted as 'coupled-enzyme-approach', which depends on the concurrent operation of two independent redox enzymes for substrate reduction and co-substrate-oxidation, respectively.[@bib9] Aiming to reduce the complexity of these redox systems,[@bib10; @bib10a; @bib10b] considerable efforts have recently been devoted to the development of nicotinamide-independent electrochemical and light-driven recycling systems for reduced flavins, which take advantage of the direct transfer of a hydride (or electrons, respectively) from a donor onto the flavin.[@bib11] In this context, the nicotinamide-independent disproportionation of enones is of appealing simplicity, since it requires only a single flavoprotein and represents a 'coupled-substrate-approach'.[@bib12]

2. Results and discussion {#sec2}
=========================

In an initial screening, a set of cloned and overexpressed enoate reductases were tested for their catalytic activity in the disproportionation of cyclohex-2-enone ([Scheme 1](#sch1){ref-type="fig"}). To our delight, the desired disproportionation activity was observed in a variety of OYE-homologs. Although all of these enoate reductase-type proteins have been reported to reduce cyclohex-2-enone to cyclohexanone at the expense of NAD(P)H,[@bib13] the corresponding disproportionation activity was exceedingly low in 12-oxophytodienoic acid reductase (OPR) isoenzymes 1 & 3 and in *N*-ethylmaleimide-, morphinone-, and pentaerythritol tetranitrate reductase. Likewise, cyclohexenone reductase from *Zymomonas mobilis* showed only modest activity, whereas the OYE-homolog YqjM[@bib14] and OYE isoenzymes[@bib15] 1 and 2 from yeast were highly active. Surprisingly, OYE isoenzyme 3 was almost inactive. The divergent behavior of OYE isoenzymes is reflected by their structural relationship: Whereas both highly active isoenzymes 1 and 2 show an amino acid sequence identity of 92%, isoenzyme 3 is a more distant relative (sequence identity 80%). The disproportionation activity of estrogen-binding protein (EBP1)[@bib3; @bib3a; @bib3b; @bib3c] could be nicely reproduced using EBP1 cloned into *Escherichia coli*. By taking the strongest disproportionation activities as a lead, further experiments were performed using YqjM, OYE1, and OYE2.

In order to convert the scrambling-like hydrogen-transfer reaction between two identical cyclohexenone molecules into a useful *directed* redox process, a pair of suitable enone substrate/co-substrate---one *only* being reduced, the other *only* being oxidized---have to be coupled. During our previous studies on NAD(P)H-dependent enone reduction, we observed that α-substituted cyclic enones were quickly reduced, whereas an alkyl-substituent in the β-position severely impeded the reaction rate.[@bib10; @bib10a; @bib10b; @bib15] Hence, we envisaged that an α-substituted enone might act as H-acceptor, while a β-substituted analog would serve as H-donor.

In order to test the viability of this concept, an equimolar amount of α- (**1**) and β-methylcyclohex-2-enone (**2**) were subjected to OYE1, OYE2, and YqjM in a nicotinamide-free buffer system ([Scheme 2](#sch2){ref-type="fig"}). The results of these experiments provided a clear proof-of-concept: Depending on the enzyme, the desired reduced α-methyl derivative **1a** was formed in up to 48% conversion, while the oxidized β-methyl analog **2b** was detected in approximately equimolar amounts.[@bib20] In contrast, only trace amounts of the corresponding cross-hydrogen-transfer products **1b** and **2a**, which would arise from undesired oxidation of **1** and reduction of **2** were found, indicating that the directed hydrogen transfer indeed worked as envisaged.

Investigation of the optical purity and absolute configuration of **1a** revealed that the product was formed in the same highly selective fashion as in the classic reduction-mode using NAD(P)H-recycling, ensuring that the chiral induction process of the enzymes remained unchanged.[@bib10b; @bib15]

In order to test the applicability of this nicotinamide-free CC-bond reduction system, we subjected two activated alkenes (**3**, **4**), which are known to be readily reduced by enoate reductases in presence of NAD(P)H,[@bib10; @bib10a; @bib10b; @bib15] to the hydrogen-transfer protocol in presence of equimolar amounts of β-methylcyclohex-2-enone (**2**) as hydrogen donor ([Scheme 3](#sch3){ref-type="fig"}). Whereas OYE1 and OYE2 showed only modest conversion, YqjM furnished the corresponding reduction products **3a** and **4a** in up to 22% conversion together with a stoichiometric amount of 3-methylphenol **2b**. Within experimental errors, the enantiomeric excess of (*R*)-configurated products **3a** and **4a** was identical to that of the nicotinamide-driven process, indicating that the enzymatic chiral induction remained intact.[@bib10; @bib10a; @bib10b; @bib15]

Since the use of equimolar amounts of 3-methylcyclohex-2-enone (**2**) as co-substrate would be economically unfavorable, a cheaper hydrogen donor was sought. After attempts using 1-indanone and hydroquinone failed, cyclohexane-1,4-dione (**5**)---yielding 1,4-dihydroxybenzene (hydroquinone, **5a**) as oxidation product---was found to provide a suitable alternative. Using YqjM, all substrates showed enhanced conversion as compared to β-methylcyclohex-2-enone (**2**) as co-substrate.

At this early stage, this novel NAD(P)H-independent cofactor recycling system has not yet been fully optimized, particularly in view of the (co)-substrate concentrations[@bib22] and the overall conversions. Incomplete conversions might be attributed to a certain degree of enzyme inhibition, most presumably caused by the co-product phenol(s), which are known to form charge-transfer complexes with flavins.[@bib23] Since the latter process is reversible, the removal of phenols by in-situ (co)-product removal (ISPR)[@bib24] using biphasic aqueous-organic solvent systems[@bib25] is the first choice. This strategy has been successfully applied to industrial scale using (flavin-dependent) enzymatic Beyer--Villiger oxidation[@bib26] and (cytochrome P~450~-dependent) alkene epoxidation mediated by whole viable cells.[@bib27]

3. Conclusion {#sec3}
=============

An novel substrate-coupled CC-bond bioreduction system was developed, which depends only on a single flavoprotein and neither requires a second (dehydrogenase) recycling enzyme, nor a nicotinamide cofactor. Due to its simplicity, it has clear advantages over other nicotinamide-independent alternative systems, such as light-driven and electrochemical FAD-recycling systems.[@bib11]

4. Experimental {#sec4}
===============

4.1. General {#sec4.1}
------------

GC--MS analyses were performed with an Agilent 7890A GC system equipped with an Agilent 5975C mass-selective detector (electron impact, 70 eV) using a (5%-phenyl)-methylpolysiloxane phase column (Agilent HP-5 ms, 30 m, 250 μm, 0.25 μm). Helium was used as carrier gas (column flow: 2 mL/min). GC--FID analyses were carried out with a Varian 3800 by using H~2~ as a carrier gas (14.5 psi). HPLC analyses were performed by using a Shimadzu system equipped with a Chiralcel OD-H column (25 cm, 0.46 cm). NMR spectra were measured on a Bruker AMX spectrometer at 360 MHz.

2-Methyl-2-cyclohexen-1-one (**1**), 2-methylcyclohexan-1-one (**1a**), 3-methylcyclohexan-1-one (**2a**) and *rac*-levodione were provided by BASF (Ludwigshafen). Cyclohexanone, 2-cyclohexen-1-one, phenol, 3-methyl-2-cyclohexen-1-one (**2**), 1,4-cyclohexanedione (**5**), hydroquinone (**5a**), and *N*-phenyl-2-methylmaleimide (**6**) were purchased from Aldrich. Citraconic acid was purchased from Alfa Aesar and 4-ketoisophorone was from ABCR Co.

4.2. Synthesis of substrates and reference materials {#sec4.2}
----------------------------------------------------

### 4.2.1. *rac*-Methylsuccinic acid {#sec4.2.1}

Citraconic acid (105 mg, 0.81 mmol) was dissolved in THF/EtOH 50:50 (10 mL) and was hydrogenated at atmospheric pressure and room temperature in the presence of 10% Pd/C (5 mg) as catalyst. After 24 h, the mixture was filtered through Celite and evaporated yielding 99% of *rac*-**1b** (106 mg, 0.80 mmol). Mp=110--115 °C. ^1^H NMR (D~2~O): *δ* 3.62--3.64 (d, 3H, *J*=7.2 Hz), 4.96--5.15 (m, 2H), 5.29--5.34 (m, 1H). ^13^C NMR (D~2~O): *δ* 18.7, 38.2, 39.6, 179.0, 182.8.[@bib15]

### 4.2.2. *rac*-Dimethyl-2-methylsuccinate (**3a**) {#sec4.2.2}

A solution of *rac*-methylsuccinic acid (32 mg, 0.24 mmol) in BF~3~/MeOH (0.5 mL, 14%) was stirred at 100 °C for 1 h. H~2~O (0.5 mL) was added and the reaction mixture was extracted with *n*-hexane (3×1 mL). The combined organic layers were dried over Na~2~SO~4~, filtered and evaporated, yielding 46% of *rac*-(**3a**) (17 mg, 0.11 mmol). ^1^H NMR (CDCl~3~): *δ* 1.22--1.24 (d, 3H, *J*=7.2 Hz), 2.39--2.45 (dd, 1H, *J*=6.06 Hz, *J*=16.52 Hz), 2.72--2.79 (dd, 1H, *J*=8.15 Hz, *J*=16.51 Hz), 2.91--2.94 (m, 1H), 3.69 (s, 3H), 3.71 (s, 3H). ^13^C NMR (CDCl~3~): *δ* 17.0, 35.7, 37.4, 51.7, 51.9, 172.3, 175.7.[@bib15]

### 4.2.3. Citraconic acid dimethylester (**3**) {#sec4.2.3}

Substrate **3** was synthesized according to the procedure described above starting from citraconic acid. ^1^H NMR (CDCl~3~): *δ* 2.06--2.07 (d, 3H, *J*=1.6 Hz), 3.73 (s, 3H), 3.83 (s, 3H), 5.86--5.87 (d, 1H, *J*=1.6 Hz). ^13^C NMR (CDCl~3~): *δ* 20.5, 51.8, 52.4, 120.6, 145.7, 165.4, 169.4.[@bib15]

### 4.2.4. *rac*-*N*-Phenyl-2-methylsuccinimide (**6a**) {#sec4.2.4}

*N*-Phenyl-2-methylmaleimide (**6**, 50 mg, 0.27 mmol) was dissolved in EtOAc (5 mL) and was hydrogenated at atmospheric pressure at room temperature using 10% Pd/C (2.8 mg) as catalyst. After 24 h, the mixture was filtered through Celite and evaporated yielding 94% of *rac*-**6a** (48 mg, 0.25 mmol). ^1^H NMR (CDCl~3~): *δ* 1.47 (d, 3H, *J*=7 Hz), 2.52 (dd, 1H, *J*=17.4 Hz, *J*=4 Hz), 3.01--3.10 (m, 1H), 3.11 (dd, 1H, *J*=17.3 Hz, *J*=9.2 Hz), 7.29--7.51 (m, 5H).[@bib15]

4.3. General procedure for the screening for enzymatic disproportionation of cyclohex-2-enone {#sec4.3}
---------------------------------------------------------------------------------------------

An aliquot of the isolated enzyme OPR1, OPR3, YqjM, OYE1, OYE2, OYE3, *Z. mobilis* ER, NEM-Red, MOR-Red, and PETN-Red (protein purity \>90%, protein content 90--110 μg/mL) was added to a Tris--HCl buffer solution (0.8 mL, 50 mM, pH 7.5) containing cyclohex-2-enone (10 mM). The mixture was shaken at 30 °C and 120 rpm for 24 h and the products were extracted with EtOAc (2×0.5 mL). The combined organic phases were dried (Na~2~SO~4~) and the resulting samples were analyzed on achiral GC. Products were identified by comparison with authentic reference materials via co-injection on GC--MS and achiral GC. Column: 6% Cyanopropyl-phenyl phase capillary column (Varian CP-1301, 30 m, 0.25 mm, 0.25 μm), detector temperature 250 °C, split ratio 30:1; temperature program: 80 °C; hold 2 min.; rise to 120 °C with 5 °C/min. *T*~Ret~: cyclohex-2-enone 2.97 min, cyclohexanone 2.43 min, phenol 4.98 min.

4.4. Hydrogen transfer between 2- (**1**) and 3-methylcyclohex-2-enone (**2**) {#sec4.4}
------------------------------------------------------------------------------

An aliquot of the isolated enzyme YqjM, OYE1, OYE2 (protein purity \>90%, protein content 90--110 μg/mL) was added to a Tris--HCl buffer solution (0.8 mL, 50 mM, pH 7.5) containing the substrate **1** (10 mM) and the co-substrate **2** (10 mM). The mixture was shaken at 30 °C and 120 rpm for 24 h and products were extracted with EtOAc (2×0.5 mL). The combined organic phases were dried (Na~2~SO~4~) and the resulting samples were analyzed on achiral GC. Products were identified by comparison with authentic reference materials via co-injection on GC--MS and achiral GC. Column: 14% cyanopropyl-phenyl phase capillary column (J&W Scientific DB-1701, 30 m, 0.25 mm, 0.25 μm), detector temperature 250 °C, split ratio 30:1. Temperature program: 110 °C, hold 5 min, rise to 200 °C with 10 °C/min, hold 2 min. *T*~Ret~: 2-methylcyclohexenone (**1**) 4.38 min; 2-methylcyclohexanone (**1a**):3.70 min; 3-methylcyclohexenone (**2**) 6.27 min; 3-methylphenol (**2b**) 7.90 min; 2-methylphenol (**1b**) 7.02 min; 3-methylcyclohexanone (**2a**) 3.63 min.

4.5. Source of enzymes {#sec4.5}
----------------------

The open reading frame of *Lycopersicon esculentum* OPR1 was cloned into pET-21a and expressed as a C-terminal hexahistidine tagged protein in *E. coli* BL21 cells. The expressed recombinant protein was purified on a Ni-NTA affinity column (Invitrogen) according to the manufacturer\'s protocol. *L. esculentum* OPR3 and YqjM from *Bacillus subtilis* were expressed and purified as reported.[@bib14; @bib28] OYE 1--3 from *Saccharomyces* sp. and NCR reductase from *Z. mobilis* were provided by BASF (Ludwigshafen).[@bib15] PETNr from *Enterobacter cloacae*, NemA from *E. coli* and MorR from *Pseudomonas putida* M10 were provided by N.C. Bruce (Department of Biology, University of York, York, UK).[@bib29]

4.6. Cloning of estrogen-binding protein EBP1 {#sec4.6}
---------------------------------------------

Two synthetic genes encoding the Estrogen-Binding Protein EBP1 from *Candida albicans*,[@bib3b] the original sequence and one with codon optimization for expression in *E. coli*, were sub-cloned into the Multiple Cloning Site of a pDHE-1650 vector (BASF vector). The pDHE-1650 vector as well as the synthetic genes were digested with NdeI and HindIII (New England Biolabs) in the corresponding buffer 2 (NEB) for 16 h at 37 °C. After purification of the digested fragments from an agarose gel (GFX PCR, DNA, gel-band purification kit, GE Healthcare), the fragments were ligated with T4 DNA ligase, provided by Roche. The resulting plasmids were transformed in *E. coli* TG1.

4.7. Sequences of the synthetic genes {#sec4.7}
-------------------------------------

### 4.7.1. Original gene {#sec4.7.1}

atgactattgaatcaactaattcatttgttgtcccatcagatactaaattaattgatgttactccattaggttcaacaaaattatttcaaccaattaaagtcggtaacaatgttttacctcaacgtattgcttatgtcccaaccaccagatttagagcttctaaagatcatattccaagtgatttacaattaaattattataatgctcgttctcaatatccaggtacattgattattactgaagcaacatttgcatctgaaagaggtggtattgatttacatgttccaggtatttataatgacgctcaagctaaaagttggaagaaaatcaatgaagcaattcatggcaatggaagtttcagttcagttcaattatggtatttaggtagagttgctaatgctaaagatttgaaagattctggattacctcttattgcgccatcagcagtttattgggatgagaatagtgaaaaattggccaaagaagctggaaatgaattgagagcattaactgaagaagaaattgatcatattgttgaagttgaatatcctaatgctgctaaacatgcacttgaagcaggatttgattatgttgaaatccatggtgctcatggttacttgttggatcagtttttaaatcttgcctctaataaaagaaccgataaatatggttgtggtagtattgaaaatcgtgcacgattattattaagagtggttgataaattaattgaagttgttggtgctaatagattggcattacgtttatcaccatgggctagtttccaaggtatggaaattgaaggtgaagaaatccattcatatattttacaacaattacaacaacgtgctgataatggtcaacaattggcttatatttctcttgttgaacctcgtgttactggtatttatgatgtttctttaaaagatcaacaaggtcgtagtaatgaatttgcttataagatttggaaaggaaattttattcgtgctggtaattatacttatgatgctccagaatttaaaactttgattaatgatttaaagaatgatcgtagtattattggattttctagatttttcacttcaaatcctgatttagtggaaaaattgaaattgggtaaaccattgaattattataatcgtgaagaattttataagtactacaactatggttataattcttatgatgaatcagaaaagcaagtcattggtaaaccattggcatagaagctt.

### 4.7.2. Synthetic gene {#sec4.7.2}

atgaccattgaaagcaccaacagctttgtggtgccgagcgataccaaactgattgatgtgaccccgctgggcagcaccaaactgtttcagccgattaaagtgggcaacaacgtgctgccgcagcgcattgcgtatgtgccgaccacccgctttcgcgcgagcaaagatcatattccgagcgatctgcagctgaactattataacgcgcgcagccagtatccgggcaccctgattattaccgaagcgacctttgcgagcgaacgcggcggcattgatctgcatgtgccgggcatttataacgatgcgcaggcgaaaagctggaaaaaaattaacgaagcgattcatggcaacggcagctttagcagcgtgcagctgtggtatctgggccgcgtggcgaacgcgaaagatctgaaagatagcggcctgccgctgattgcgccgagcgcggtgtattgggatgaaaacagcgaaaaactggcgaaagaagcgggcaacgaactgcgcgcgctgaccgaagaagaaattgatcatattgtggaagtggaatatccgaacgcggcgaaacatgcgctggaagcgggctttgattatgtggaaattcatggcgcgcatggctatctgctggatcagtttctgaacctggcgagcaacaaacgcaccgataaatatggctgcggcagcattgaaaaccgcgcgcgcctgctgctgcgcgtggtggataaactgattgaagtggtgggcgcgaaccgcctggcgctgcgcctgagcccgtgggcgagctttcagggcatggaaattgaaggcgaagaaattcatagctatattctgcagcagctgcagcagcgcgcggataacggccagcagctggcgtatattagcctggtggaaccgcgcgtgaccggcatttatgatgtgagcctgaaagatcagcagggccgcagcaacgaatttgcgtataaaatttggaaaggcaactttattcgcgcgggcaactatacctatgatgcgccggaatttaaaaccctgattaacgatctgaaaaacgatcgcagcattattggctttagccgcttttttaccagcaacccggatctggtggaaaaactgaaactgggcaaaccgctgaactattataaccgcgaagaattttataaatattataactatggctataacagctatgatgaaagcgaaaaacaggtgattggcaaaccgctggcgtagctaagctt.

4.8. Expression of estrogen-binding protein EBP1 {#sec4.8}
------------------------------------------------

The enzymes were expressed in *E. coli TG1* (Stratagene). LB medium (2 ml) with antibiotic supplement (100 μg/μL ampicillin) were inoculated with a single colony of *E. coli TG1* pDHE-EBP1 and incubated with shaking (220 rpm) for 5 h at 37 °C. This culture was diluted 1:100 with fresh LB medium (100 μg/μL, 2 g/L rhamnose, the pDHE vector has a rhamnose-inducible promoter) and incubated with shaking (220 rpm) for 16 h at 37 °C. Then the cells were harvested by centrifugation (5 min, 10,000 rpm) and washed with 50 mM Tris--HCl pH 7.5. The cell pellet was used for further experiments.

4.9. General procedure for the bioreduction of activated alkenes **3**, **4**, and **6** using 3-methyl-2-cyclohexen-1-one (**2**) or 1,4-cyclohexanedione (**5**) as H-donor {#sec4.9}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

An aliquot of isolated enzyme OYE1, OYE2, and YqjM (protein purity \>90%, protein content 90--110 μg/mL) was added to a Tris--HCl buffer solution (0.8 mL, 50 mM, pH 7.5) containing substrate (**3**, **4**, or **6**, 10 mM) and 3-methyl-2-cyclohexen-1-one (**2**) or 1,4,-cyclohexanedione (**5**) (10 mM). The mixture was shaken at 30 °C and 120 rpm for 24 h and the products were extracted with EtOAc (2×0.5 mL). The combined organic phases were dried (Na~2~SO~4~) and the resulting samples were analyzed on achiral GC--MS and achiral GC. Column: 14% cyanopropyl-phenyl phase capillary column, J&W Scientific DB-1701, 30 m, 0.25 mm, 0.25 μm, detector temperature 250 °C, split ratio 30:1. Temperature program: 110 °C, hold 5 min, rise to 200 °C with 10 °C/min, hold 4 min. *T*~Ret~: 3-Methylcyclohexenone (**2**) 6.27 min; 3-methylcyclohexanone (**2a**) 3.63 min; citraconic acid dimethylester (**3**) 6.91 min; dimethyl-2-methylsuccinate (**3a**) 5.89 min; 4-ketoisophorone (**4**) 8.22 min; levodion (**4a**) 9.26 min; 1,4,-cyclohexanedione (**5**) 8.38 min; hydroquinone (**5a**) 13.51 min; *N*-phenyl-2-methylmaleimide (**6**) 15.84 min; *N*-phenyl-2-methylsuccinimide (**6a**) 14.12 min;

4.10. Determination of enantiomeric excess and absolute configuration {#sec4.10}
---------------------------------------------------------------------

The enantiomeric excess of **1a** and **3a** was determined using a modified β-cyclodextrin capillary column (Chiraldex B-TA, 40 m, 0.25 mm). Detector temperature 200 °C, injector temperature 180 °C, split ratio 25:1. Temperature program for **1a**: 80 °C hold 2 min, 5 °C/min to 105 °C, 10 °C/min, hold 4 min. Retention times: (*R*)-**1a** 6.34 and (*S*)-**1a** 6.47 min. Temperature program for **3a**: 90 °C hold 4 min, 3 °C/min to 115 °C, 30 °C/min to 180 °C. Retention times: (*S*)-**3b** 7.33 min; (*R*)-**3b** 7.45 min; The enantiomeric excess of **4a** was determined using a β-cyclodextrin capillary column (CP-Chirasil-DEX CB, 25 m, 0.32 mm, 0.25 μm film). Temperature program for **4a**: 90 °C hold 2 min, 4 °C/min to 115 °C, 20 °C/min to 180 °C, hold 2 min. Retention times: (*R*)-**4a** 6.42; (*S*)-**4a** 6.74 min. The enantiomeric excess of **8b** was determined on HPLC using *n*-heptane/*i*-PrOH 95:5 (isocratic) at 18 °C and 1 mL/min. Retention times: (*R*)-**8b** 25.10 min; (*S*)-**8b** 29.15 min.[@bib15]

This work was partially financed by the Fonds zur Förderung der wissenschaftlichen Fortschung (FWF, Vienna, project no. 18689); N.C. Bruce and H. Housden (University of York) are cordially thanked for providing samples of *N*-ethylmaleimide-, morphinone- and PETN-reductase.

![Disproportionation of cyclohex-2-ene catalyzed by enoate reductases.^a^OPR1, OPR3=oxophytodienoate reductase isoenzymes 1 and 3, respectively, from tomato;[@bib16] NEM-reductase=*N*-ethylmaleimide reductase;[@bib18] MOR-reductase=morphinone reductase;[@bib17] PETN-reductase=pentaerythritol tetranitrate reductase;[@bib18]*Z. mobilis* NCR reductase=nicotinamide-dependent cyclohexenone reductase;[@bib19] YqjM=OYE-homolog from *Bacillus subtilis*;[@bib14] OYE1--3=Old Yellow Enzyme isoenzymes from yeasts;[@bib15] EBP1=estrogen-binding protein,[@bib3] employed as cell-free extract of *E. coli* expressing EBP1.](sc1){#sch1}

![Asymmetric hydrogen transfer between α- (**1**) and β-methylcyclohex-2-enone (**2**) catalyzed by enoate reductases.](sc2){#sch2}

![Asymmetric bioreduction of activated alkenes via a coupled-substrate approach. n.d.=not determined. ^a^A trace of 2,3-epoxy-2,6,6-trimethylcyclohexane-1,4-dione was formed (≤3%), presumably due to spontaneous epoxidation of the CC-bond by H~2~O~2~ derived via enzyme-catalyzed reduction of O~2~.[@bib21]^b^A trace of aniline was detected as side product (≤3%).](sc3){#sch3}
